Femasys Inc. Logo

Femasys Inc.

FEMY

(1.8)
Stock Price

1,17 USD

-85.08% ROA

-99.27% ROE

-1.13x PER

Market Cap.

20.558.460,00 USD

27.41% DER

0% Yield

-1156.08% NPM

Femasys Inc. Stock Analysis

Femasys Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Femasys Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.98x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-78.99%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-80.69%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Femasys Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Femasys Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Femasys Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Femasys Inc. Revenue
Year Revenue Growth
2019 929.064
2020 1.037.918 10.49%
2021 1.179.689 12.02%
2022 1.206.218 2.2%
2023 977.444 -23.41%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Femasys Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2019 6.914.179
2020 4.130.613 -67.39%
2021 4.084.304 -1.13%
2022 5.813.755 29.75%
2023 8.291.320 29.88%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Femasys Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 3.298.829
2020 2.544.043 -29.67%
2021 4.262.002 40.31%
2022 5.430.704 21.52%
2023 7.881.632 31.1%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Femasys Inc. EBITDA
Year EBITDA Growth
2019 -10.164.346
2020 -5.799.875 -75.25%
2021 -6.923.551 16.23%
2022 -10.813.173 35.97%
2023 -14.951.748 27.68%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Femasys Inc. Gross Profit
Year Gross Profit Growth
2019 705.386
2020 731.385 3.55%
2021 809.305 9.63%
2022 764.280 -5.89%
2023 632.700 -20.8%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Femasys Inc. Net Profit
Year Net Profit Growth
2019 -11.271.948
2020 -6.914.992 -63.01%
2021 -7.537.845 8.26%
2022 -11.394.170 33.84%
2023 -15.987.620 28.73%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Femasys Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -1
2020 -1 0%
2021 -1 100%
2022 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Femasys Inc. Free Cashflow
Year Free Cashflow Growth
2019 -11.702.495
2020 -4.964.696 -135.71%
2021 -8.237.653 39.73%
2022 -11.139.448 26.05%
2023 -2.882.911 -286.4%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Femasys Inc. Operating Cashflow
Year Operating Cashflow Growth
2019 -11.005.996
2020 -4.933.015 -123.11%
2021 -7.930.785 37.8%
2022 -10.731.973 26.1%
2023 -2.855.742 -275.8%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Femasys Inc. Capital Expenditure
Year Capital Expenditure Growth
2019 696.499
2020 31.681 -2098.48%
2021 306.868 89.68%
2022 407.475 24.69%
2023 27.169 -1399.78%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Femasys Inc. Equity
Year Equity Growth
2019 -45.372.556
2020 -51.815.728 12.43%
2021 26.332.382 296.78%
2022 15.242.519 -72.76%
2023 10.443.602 -45.95%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Femasys Inc. Assets
Year Assets Growth
2019 12.646.217
2020 7.606.318 -66.26%
2021 28.576.680 73.38%
2022 16.895.570 -69.14%
2023 14.853.537 -13.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Femasys Inc. Liabilities
Year Liabilities Growth
2019 58.018.773
2020 59.422.046 2.36%
2021 2.244.298 -2547.69%
2022 1.653.051 -35.77%
2023 4.409.935 62.52%

Femasys Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.07
Net Income per Share
-0.84
Price to Earning Ratio
-1.13x
Price To Sales Ratio
18.81x
POCF Ratio
-1.29
PFCF Ratio
-1.82
Price to Book Ratio
1.37
EV to Sales
13.47
EV Over EBITDA
-1.24
EV to Operating CashFlow
-1.33
EV to FreeCashFlow
-1.3
Earnings Yield
-0.88
FreeCashFlow Yield
-0.55
Market Cap
0,02 Bil.
Enterprise Value
0,01 Bil.
Graham Number
3.61
Graham NetNet
0.31

Income Statement Metrics

Net Income per Share
-0.84
Income Quality
0.87
ROE
-0.99
Return On Assets
-0.85
Return On Capital Employed
-1.03
Net Income per EBT
0.99
EBT Per Ebit
0.97
Ebit per Revenue
-11.95
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
5.54
Research & Developement to Revenue
5.86
Stock Based Compensation to Revenue
0.63
Gross Profit Margin
0.65
Operating Profit Margin
-11.95
Pretax Profit Margin
-11.64
Net Profit Margin
-11.56

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.04
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.74
Free CashFlow per Share
-0.75
Capex to Operating CashFlow
0.02
Capex to Revenue
-0.18
Capex to Depreciation
-0.22
Return on Invested Capital
-0.83
Return on Tangible Assets
-0.85
Days Sales Outstanding
34.58
Days Payables Outstanding
802.96
Days of Inventory on Hand
568.06
Receivables Turnover
10.56
Payables Turnover
0.45
Inventory Turnover
0.64
Capex per Share
-0.01

Balance Sheet

Cash per Share
0,58
Book Value per Share
0,69
Tangible Book Value per Share
0.69
Shareholders Equity per Share
0.69
Interest Debt per Share
0.19
Debt to Equity
0.27
Debt to Assets
0.19
Net Debt to EBITDA
0.49
Current Ratio
4.68
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0.27
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
592071
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Femasys Inc. Dividends
Year Dividends Growth

Femasys Inc. Profile

About Femasys Inc.

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

CEO
Ms. Kathy Lee-Sepsick
Employee
34
Address
3950 Johns Creek Court
Suwanee, 30024

Femasys Inc. Executives & BODs

Femasys Inc. Executives & BODs
# Name Age
1 Mr. Richard Spector
Chief Commercial Officer
70
2 Mr. Daniel Scott Currie
Chief Operating Officer, Senior Vice President & Secretary
70
3 Ms. Kathy Lee-Sepsick
Founder, President, Chief Executive Officer & Director
70
4 Dr. James H. Liu M.D.
Chief Medical Officer
70
5 Mr. Dov Elefant
Chief Financial Officer
70
6 Ms. Mary An Merchant J.D., Ph.D.
Vice President of Counsel & Intellectual Property
70
7 Dr. Jeffrey Marcus M.D., M.S.
Chief Medical Advisor
70
8 Ms. Christine Thomas
Senior Vice President of Regulatory & Clinical Affairs
70

Femasys Inc. Competitors